Bevacizumab/Irinotecan. Un nouveau traitement actif dans les gliomes de haut grade récidivants : résultats préliminaires d’une étude multicentrique de l’Anocef
- 31 July 2008
- journal article
- research article
- Published by Elsevier in Revue Neurologique
- Vol. 164 (6-7) , 588-594
- https://doi.org/10.1016/j.neurol.2008.04.003
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3The Lancet Oncology, 2008
- Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomasJournal of Clinical Oncology, 2007
- Bevacizumab plus irinotecan therapy in relapsed, heavily pre-treated malignant glioma: A case seriesJournal of Clinical Oncology, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon CancerArchives of Neurology, 2006
- Temozolomide in the treatment of recurrent malignant gliomaCancer, 2004
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11Neuro-Oncology, 2004
- Factors influencing survival in high-grade gliomasSeminars in Oncology, 2003
- Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394Journal of Clinical Oncology, 2003
- Irinotecan Therapy in Adults With Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 1999